112887-43-1

Basic information

• Product Name: 4-Benzyl-2-(2-hydroxyethyl)morpholine
• Synonyms: 4-Benzyl-2-(2-hydroxyethyl)morpholine
• CAS NO: 112887-43-1
• Molecular Formula: C₁₃H₁₉NO₂
• Molecular Weight: 221.3
• Product Categories: pharmacetical
• Mol File: 112887-43-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 337.5°Cat760mmHg
• Flash Point: 157.9°C
• Appearance: /
• Density: 1.095g/cm³
• Vapor Pressure: 4.08E-05mmHg at 25°C
• Refractive Index: 1.542
• CAS DataBase Reference: 4-Benzyl-2-(2-hydroxyethyl)morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Benzyl-2-(2-hydroxyethyl)morpholine(112887-43-1)
• EPA Substance Registry System: 4-Benzyl-2-(2-hydroxyethyl)morpholine(112887-43-1)

Safety Data

• Hazardous Substances Data: 112887-43-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C13H19NO2/c15-8-6-13-11-14(7-9-16-13)10-12-4-2-1-3-5-12/h1-5,13,15H,6-11H2

Upstream product

• 73933-19-4 ethyl 4-(phenylmethyl)-2-morpholineacetate 
• 122894-54-6 2-(2-chloroethyl)-4-(phenylmethyl)morpholine 
• 104-63-2 N-Benzylethanolamine 

Downstream Products

• 126645-72-5 N-<2-(4-benzyl-2-morpholinyl)ethyl>phthalimide 
• 122894-54-6 2-(2-chloroethyl)-4-(phenylmethyl)morpholine 
• 112914-08-6 2-(2-aminoethyl)-4-benzylmorpholine 
• 126645-69-0 4-amino-N-[2-(4-benzyl-2-morpholinyl)ethyl]-5-chloro-2-ethoxybenzamide 
• 126645-68-9 4-amino-N-[2-(4-benzyl-2-morpholinyl)ethyl]-5-chloro-2-methoxybenzamide 
• 132995-76-7 (2-hydroxyethyl)-morpholine 
• 1185190-87-7 4-benzyl-2-(2-methoxyethyl)morpholine 
• 1398371-20-4 2-(4-(2-(2-(((R)-1-(naphthalen-1-yl)ethyl)amino)ethyl)morpholino)phenoxy)acetic acid 
• 1005474-71-4 tert-butyl 2-(2-(tosyloxy)ethyl)morpholine-4-carboxylate 
• 913642-78-1 (±)-tert-butyl 2-(2-hydroxyethyl)morpholine-4-carboxylate 
• 1398495-34-5 2-(4-(2-(2-(((R)-1-(naphthalen-1-yl)ethyl)amino)ethyl)morpholino)phenoxy)acetic acid 
• 1398495-52-7 4-((2-(2-(((R)-1-(naphthalen-1-yl)ethyl)amino)ethyl)morpholino)methyl)benzoic acid 

Relevant articles and documents

INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE

Bifunctional compounds, which find utility as modulators of leucine-rich repeat kinase 2 (LRRK2), are described herein. In particular, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds LRRK2, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The hetero-bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR

Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (Ca SR) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (Ca SR) receptors of Formula (I).

Novel benzamides as selective and potent gastric prokinetic agents. 1. Synthesis and structure-activity relationships of N-[(2-morpholinyl)alkyl]benzamides

With the purpose of obtaining more potent and selective gastric prokinetic agents than metoclopramide (1), a new series of N-[(2-morpholinyl)alkyl]benzamides (17-52) were synthesized and their gastric prokinetic activity was evaluated by determining effect on the gastric emptying of phenol red semisolid meal and of resin pellets solid meal in rats and mice. The morpholinyl moiety was newly designed after consideration of the side-chain structure of cisapride (2) and produced the desired activity when coupled with the 4-amino-5-chloro-2-methoxybenzoyl group of both metoclopramide and cisapride. Modification of the substituents of the benzoyl group markedly influenced the activity. In particular, 4-amino-N-[benzyl-2-morpholinyl)methyl]-5-chloro-2-methoxybenzamide (17) and the 4-(dimethylamino) and 2-ethoxy analogues (25 and 29) or 17 showed potent and selective gastric prokinetic activity along with a weak dopamine D2 receptor antagonistic activity.